ACADIA Pharmaceuticals Inc. (ACAD) carries a Roarable Rating of C+ (Hold) with 66/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
As of 2026-11-01, ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 66/100 at a spot price of $20.76 (+2.17% 1D, market cap $3.58B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 14/20. Across 1016 tracked Health Care issuers, ACAD ranks #127 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ACAD carries a Roarable C+ (66/100 RQD), trailing P/E of 9.1x, gross margin of 91.7%, and ROIC of 7.9%. By comparison, AMLX (Amylyx Pharmaceuticals Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $3.60B) and OGN (Organon & Co.) posts a C- grade (61/100 RQD, P/E 19.4x, ROIC 24.9%, cap $3.63B). Among the 5-stock peer group, ACAD leads on earnings multiple (9.1x) while OGN leads on capital efficiency (24.9% ROIC).
Per ACAD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001070494), ACADIA Pharmaceuticals Inc. generated $1.07B in revenue (+11.9% YoY), $391.0M in net income, and $105.1M in free cash flow against $1.56B in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 6.26 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
FRED Regime × Technicals: 19% of 52W Range • RSI-14 at 45.5 (NEUTRAL RANGE)
Capital intensity & 9.8% operating margin leave 12 pts on the table
Even with a 66/100 (C+) score, ACAD faces multiple-compression risk if 9.1x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Broader market pullbacks can still drag down strong stocks in the short run.
Dilution & Margin Drag: Cannibal Buyback (-1.80% YoY Shares) — any gross margin slip below 89.2% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($23.74) or 200D SMA ($23.68) invalidates the momentum regime and cuts Target Base ($21.51) toward Bear Floor ($16.78).
ACADIA Pharmaceuticals Inc. (ACAD) surged +2.17% to $20.76, trading at 19% of its 52-week range ($18.39 – $30.96). Solid 92% profit margin (8% return on capital), mixed timing at 9x P/E—hold if owned, no rush to chase.
Regenxbio (RGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO, October 28, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the UBS Global Biopharma Conference 2026 on Tuesday, November 17, 2026 at 12:40 p.m.
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO, October 21, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter 2026 financial results on Wednesday, November 4, 2026, after the close of the U.S. financial marke
AXSM's Auvelity sales surged 54.2% to $333 million in the first half of 2026. New indications could further expand its growth potential.
Needham analyst Ami Fadia reiterates Acadia Pharmaceuticals (NASDAQ:ACAD) with a Buy and maintains $35 price target.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +11.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ACAD today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ACAD. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, ACADIA Pharmaceuticals Inc. (ACAD) ranks #127 by composite RQD confidence (66/100, grade C+) and #193 by equity capitalization ($3.58B). Within this direct 5-issuer industry benchmark cohort, ACAD leads on earnings valuation at 9.1x trailing P/E, while OGN leads on capital efficiency and profitability with 24.9% ROIC and 53.3% gross margin. ACAD currently leads its immediate peer cohort in composite quantitative strength at 66/100 (C+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ACAD
ACTIVE
ACADIA Pharmaceuticals Inc. | C+ | 66/100 | 9.1x | 91.7% | 7.9% | +2.17% | $3.58B | Benchmark Subject |
| AMLX Amylyx Pharmaceuticals Inc. | D- | 38/100 | — | — | -35.0% | +2.17% | $3.60B | /amlx-vs-acad → |
| OGN Organon & Co. | C- | 61/100 | 19.4x | 53.3% | 24.9% | +0.22% | $3.63B | /ogn-vs-acad → |
| XENE Xenon Pharmaceuticals Inc. | D- | 37/100 | — | — | -35.0% | +3.30% | $3.64B | /xene-vs-acad → |
| PBLS Parabilis Medicines Inc. | C- | 60/100 | — | — | — | +1.88% | $3.50B | /pbls-vs-acad → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), ACADIA Pharmaceuticals Inc. (ACAD) reported GAAP revenue of $1.07B (+11.9% vs. FY2024 revenue of $957.8M , and +47.5% cumulative change since FY2023) , GAAP net income of $391.0M, operating cash flow of $109.8M, and free cash flow of $105.1M (-33.1% YoY). On the balance sheet, ACAD closed FY2025 with $1.56B in total assets against $0 in total debt (Altman Z-Score: 6.26, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $1.07B | $391.0M | $109.8M | $105.1M | $1.56B | — |
| FY2024 (FY) | 2024-12-31 | $957.8M | $226.0M | $157.7M | $157.2M | $1.19B | — |
| FY2023 (FY) | 2023-12-31 | $726.4M | -$61.0M | $16.7M | $16.7M | — | — |
As of 2026-11-01, ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 66/100 at a spot price of $20.76 (+2.17% 1D, market cap $3.58B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 14/20. Across 1016 tracked Health Care issuers, ACAD ranks #127 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ACAD carries a Roarable C+ (66/100 RQD), trailing P/E of 9.1x, gross margin of 91.7%, and ROIC of 7.9%. By comparison, AMLX (Amylyx Pharmaceuticals Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $3.60B) and OGN (Organon & Co.) posts a C- grade (61/100 RQD, P/E 19.4x, ROIC 24.9%, cap $3.63B). Among the 5-stock peer group, ACAD leads on earnings multiple (9.1x) while OGN leads on capital efficiency (24.9% ROIC).
Per ACAD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001070494), ACADIA Pharmaceuticals Inc. generated $1.07B in revenue (+11.9% YoY), $391.0M in net income, and $105.1M in free cash flow against $1.56B in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
ACAD last traded at $20.76 (+2.17% on volume of 2,193,872 shares), positioning the stock -12.55% below its 50-day simple moving average ($23.74) and -12.33% below its 200-day simple moving average ($23.68). Across its 52-week range of $18.39 to $30.96, ACAD sits at the 18.9% percentile with a 14-day RSI of 45.5 (NEUTRAL RANGE) and an implied next-earnings move of ±6.4% ($19.43 to $22.09).
Why ACAD Stock surged +2.17% Today — RQD Quant Desk Flash. Solid 92% profit margin (8% return on capital), mixed timing at 9x P/E—hold if owned, no rush to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).